{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T18:37:33Z","timestamp":1776710253015,"version":"3.51.2"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriasis, a chronic inflammatory skin disease affecting 2\u20133% of the global population, is driven by dysregulated immune responses. Despite advancements in biologic therapies, treatment challenges persist due to high recurrence rates. This study aimed to identify immune-related hub genes and elucidate their clinical implications in psoriasis pathogenesis and therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Multiple microarray datasets from psoriasis patients (GSE30999, GSE106992, GSE14905, GSE78097, and GSE117468) were obtained to identify immune-key genes by differential gene analysis and Weighted Gene Co-expression Network Analysis (WGCNA). Subsequently, immune-related hub genes were identified using the Least Absolute Shrinkage and Selection Operator (LASSO) algorithm and Protein-Protein Interaction (PPI) networks, with further validation through Gene Set Enrichment Analysis (GSEA) and Receiver Operating Characteristic (ROC) curves to assess exploratory within-sample discrimination. Pearson correlation analysis evaluated the relationship between hub genes, skin lesion severity, and treatment outcomes. The study also conducted immune infiltration by using the Cell-type Identification by Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) algorithm and identified potential therapeutic targets by the Drug-Gene Interaction Database (DGIdb).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-one immune-related key genes were identified, and six hub genes (\n                      <jats:italic>CLEC7A, CXCL1, IRF1, S100A12, S100A8, S100A9<\/jats:italic>\n                      ) were validated as central players in immune signaling pathways. These genes exhibited within-sample discrimination (AUC\u2009&gt;\u20090.9) and correlated with disease severity and biological therapy efficacy. Immune infiltration analysis revealed increased activated memory CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells and M1 macrophages in lesional skin, which was strongly associated with hub gene expression. Additionally, drug-gene interaction analysis identified potential therapeutic agents targeting these genes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study identified six immune-related hub genes that were closely linked to the severity of psoriasis, the effectiveness of biological treatments, and infiltrated activated memory CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells and M1 macrophages. Our findings elucidate a novel immune-related hub gene network in psoriasis and provide potential targets for the development and application of biologics.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0347536","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:38:51Z","timestamp":1776706731000},"page":"e0347536","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification and clinical implications of immune-related hub genes in psoriasis"],"prefix":"10.1371","volume":"21","author":[{"given":"Yuzhen","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziguang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-4093","authenticated-orcid":true,"given":"Weiyuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"19","key":"pone.0347536.ref001","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"AW Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"pone.0347536.ref002","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00403-024-02846-z","article-title":"Global burden and future trends in psoriasis epidemiology: insights from the global burden of disease study 2019 and predictions to 2030","volume":"316","author":"K Wang","year":"2024","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"pone.0347536.ref003","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3892\/etm.2022.11124","article-title":"Update on the etiopathogenesis of psoriasis","volume":"23","author":"DE Branisteanu","year":"2022","journal-title":"Exp Ther Med"},{"issue":"4","key":"pone.0347536.ref004","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40257-020-00521-3","article-title":"Treatment goals in psoriasis: which outcomes matter most?","volume":"21","author":"SA Svoboda","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"pone.0347536.ref005","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"J Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"pone.0347536.ref006","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaci.2024.05.008","article-title":"Inflammatory memory in psoriasis: from remission to recurrence","volume":"154","author":"L Francis","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"pone.0347536.ref007","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41423-022-00940-8","article-title":"The epidermal immune microenvironment plays a dominant role in psoriasis development, as revealed by mass cytometry","volume":"19","author":"Y Zhou","year":"2022","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"pone.0347536.ref008","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12950-023-00360-z","article-title":"Advances in the study of macrophage polarization in inflammatory immune skin diseases","volume":"20","author":"T Xia","year":"2023","journal-title":"J Inflamm (Lond)"},{"issue":"5","key":"pone.0347536.ref009","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jaci.2021.04.021","article-title":"Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets","volume":"148","author":"J Kim","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"pone.0347536.ref010","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250354","article-title":"Single-cell transcriptomics reveals prominent expression of IL-14, IL-18, and IL-32 in psoriasis","volume":"53","author":"B Frost","year":"2023","journal-title":"Eur J Immunol"},{"issue":"11","key":"pone.0347536.ref011","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1038\/jid.2012.184","article-title":"Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis","volume":"132","author":"M Su\u00e1rez-Fari\u00f1as","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"2","key":"pone.0347536.ref012","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jid.2016.09.015","article-title":"Shrinking the psoriasis assessment gap: early gene-expression profiling accurately predicts response to long-term treatment","volume":"137","author":"J Correa da Rosa","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"5","key":"pone.0347536.ref013","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.jaci.2019.01.017","article-title":"Modulation of inflammatory gene transcripts in psoriasis vulgaris: differences between ustekinumab and etanercept","volume":"143","author":"C Brodmerkel","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"pone.0347536.ref014","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4049\/immunohorizons.2300003","article-title":"Guselkumab more effectively neutralizes psoriasis-associated histologic, transcriptomic, and clinical measures than ustekinumab","volume":"7","author":"K Campbell","year":"2023","journal-title":"ImmunoHorizons"},{"issue":"7","key":"pone.0347536.ref015","article-title":"Type I interferon: potential therapeutic target for psoriasis?","volume":"3","author":"Y Yao","year":"2008","journal-title":"PLoS One"},{"issue":"11","key":"pone.0347536.ref016","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.jid.2016.04.032","article-title":"The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes.","volume":"136","author":"J Kim","year":"2016","journal-title":"J invest Dermatol"},{"issue":"3","key":"pone.0347536.ref017","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaci.2019.10.041","article-title":"Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis","volume":"145","author":"LE Tomalin","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"pone.0347536.ref018","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","article-title":"Adjusting batch effects in microarray expression data using empirical Bayes methods","volume":"8","author":"WE Johnson","year":"2007","journal-title":"Biostatistics"},{"issue":"1","key":"pone.0347536.ref019","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer Immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"P Charoentong","year":"2017","journal-title":"Cell Rep"},{"issue":"5","key":"pone.0347536.ref020","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"AM Newman","year":"2015","journal-title":"Nat Methods"},{"key":"pone.0347536.ref021","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-1-0716-0301-7_7","article-title":"Profiling cell type abundance and expression in bulk tissues with CIBERSORTx","volume":"2117","author":"CB Steen","year":"2020","journal-title":"Methods Mol Biol"},{"key":"pone.0347536.ref022","article-title":"DGIdb 5.0: rebuilding the drug-gene interaction database for precision medicine and drug discovery platforms","author":"M Cannon","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"pone.0347536.ref023","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bjd.17208","article-title":"Risk of first-time and recurrent depression in patients with psoriasis: a population-based cohort study","volume":"180","author":"A Egeberg","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"pone.0347536.ref024","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1186\/s12889-023-16758-6","article-title":"Factors associated with quality of life in Chinese people with psoriasis: a cross-sectional study","volume":"23","author":"X-J Zhang","year":"2023","journal-title":"BMC Public Health"},{"key":"pone.0347536.ref025","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"R Parisi","year":"2020","journal-title":"BMJ"},{"issue":"8","key":"pone.0347536.ref026","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41573-023-00735-0","article-title":"Disease modification in inflammatory skin disorders: opportunities and challenges","volume":"22","author":"T Bieber","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"pone.0347536.ref027","article-title":"Uncovering common disease mechanisms and critical biomarkers in Crohn\u2019s disease with concurrent psoriasis and exploring potential therapeutic agents","volume":"20","author":"T Liu","year":"2025","journal-title":"PLoS One"},{"key":"pone.0347536.ref028","doi-asserted-by":"crossref","first-page":"17448069221128423","DOI":"10.1177\/17448069221128423","article-title":"ARG1 and CXCL2 are potential biomarkers target for psoriasis patients","volume":"18","author":"H Wang","year":"2022","journal-title":"Mol Pain"},{"issue":"10275","key":"pone.0347536.ref029","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"K Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"pone.0347536.ref030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"MA Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"issue":"9494","key":"pone.0347536.ref031","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"K Reich","year":"2005","journal-title":"Lancet"},{"issue":"8","key":"pone.0347536.ref032","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamainternmed.2020.2033","article-title":"Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19","volume":"180","author":"W Liang","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"8","key":"pone.0347536.ref033","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"A Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"pone.0347536.ref034","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"D Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"pone.0347536.ref035","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaa358","article-title":"Progress and challenge for computational quantification of tissue immune cells","volume":"22","author":"Z Chen","year":"2021","journal-title":"Brief Bioinform"},{"issue":"11","key":"pone.0347536.ref036","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1038\/jid.2010.196","article-title":"A comprehensive analysis of pattern recognition receptors in normal and inflamed human epidermis: upregulation of dectin-1 in psoriasis","volume":"130","author":"HD de Koning","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"2","key":"pone.0347536.ref037","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1684\/ejd.2024.4662","article-title":"IL-17A and TNF-\u03b1-induced Dectin-1 expression may promote keratinocyte proliferation in psoriatic lesions","volume":"34","author":"W Cui","year":"2024","journal-title":"Eur J Dermatol"},{"issue":"1","key":"pone.0347536.ref038","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1523-1747.1998.00074.x","article-title":"The CXC receptor 2 is overexpressed in psoriatic epidermis","volume":"110","author":"R Kulke","year":"1998","journal-title":"J Invest Dermatol"},{"key":"pone.0347536.ref039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2022.01.004","article-title":"Revisiting IRF1-mediated antiviral innate immunity","volume":"64","author":"H Zhou","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"pone.0347536.ref040","doi-asserted-by":"crossref","first-page":"109478","DOI":"10.1016\/j.intimp.2022.109478","article-title":"IFIH1\/IRF1\/STAT1 promotes sepsis associated inflammatory lung injury via activating macrophage M1 polarization","volume":"114","author":"A Wang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"pone.0347536.ref041","doi-asserted-by":"crossref","first-page":"155412","DOI":"10.1016\/j.phymed.2024.155412","article-title":"Formononetin attenuates psoriasiform inflammation by regulating interferon signaling pathway","volume":"128","author":"H-T Xu","year":"2024","journal-title":"Phytomedicine"},{"issue":"9","key":"pone.0347536.ref042","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41584-018-0058-9","article-title":"S100 proteins in rheumatic diseases","volume":"14","author":"J Austermann","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"pone.0347536.ref043","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s10020-023-00662-1","article-title":"S100 proteins in cardiovascular diseases","volume":"29","author":"Y Zhou","year":"2023","journal-title":"Mol Med"},{"issue":"2","key":"pone.0347536.ref044","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrc3893","article-title":"S100 proteins in cancer","volume":"15","author":"AR Bresnick","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"pone.0347536.ref045","doi-asserted-by":"crossref","first-page":"1191645","DOI":"10.3389\/fimmu.2023.1191645","article-title":"Pathogenic role of S100 proteins in psoriasis","volume":"14","author":"H Liang","year":"2023","journal-title":"Front Immunol"},{"key":"pone.0347536.ref046","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3389\/fimmu.2017.01908","article-title":"S100 proteins as an important regulator of macrophage inflammation","volume":"8","author":"C Xia","year":"2017","journal-title":"Front Immunol"},{"issue":"11","key":"pone.0347536.ref047","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1016\/j.jid.2022.05.1085","article-title":"Association of S100A8\/A9 with lipid-rich necrotic core and treatment with biologic therapy in patients with psoriasis: results from an observational cohort study","volume":"142","author":"AR Berg","year":"2022","journal-title":"J Invest Dermatol"},{"key":"pone.0347536.ref048","doi-asserted-by":"crossref","first-page":"599947","DOI":"10.3389\/fimmu.2020.599947","article-title":"Interleukin 17 promotes expression of alarmins S100A8 and S100A9 during the inflammatory response of keratinocytes","volume":"11","author":"C Christmann","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"pone.0347536.ref049","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4049\/jimmunol.2000087","article-title":"Deletion of S100a8 and S100a9 enhances skin hyperplasia and promotes the Th17 response in imiquimod-induced psoriasis","volume":"206","author":"J Defr\u00eane","year":"2021","journal-title":"J Immunol"},{"issue":"7","key":"pone.0347536.ref050","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/jdv.13269","article-title":"Among the S100 proteins, S100A12 is the most significant marker for psoriasis disease activity","volume":"30","author":"D Wilsmann-Theis","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"pone.0347536.ref051","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10753-024-02073-8","article-title":"Targeting S100A12 to improve angiogenesis and accelerate diabetic wound healing","volume":"48","author":"S Qin","year":"2025","journal-title":"Inflammation"},{"key":"pone.0347536.ref052","doi-asserted-by":"crossref","first-page":"606065","DOI":"10.3389\/fgene.2021.606065","article-title":"Identification of hub genes and immune infiltration in psoriasis by bioinformatics method","volume":"12","author":"W Su","year":"2021","journal-title":"Front Genet"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0347536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:39:00Z","timestamp":1776706740000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0347536"}},"subtitle":[],"editor":[{"given":"Charushila Yuvraj","family":"Kadam","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0347536","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]}}}